A major new study links popular sweeteners to faster cognitive decline. For microscopic colitis (MC) patients, there's a second layer of risk that most coverage isn't mentioning.

Many of us turned to artificial sweeteners and sugar alcohols years ago, to manage weight, control blood sugar, reduce calories, or simply because we were told they were a safer alternative to sugar. A major new study published in Neurology, the journal of the American Academy of Neurology, suggests that for at least some of those sweeteners, the "safer" assumption may have been wrong. And for MC patients, the concerns go beyond the brain.

Researchers at the University of Sao Paulo followed nearly 13,000 Brazilian adults with an average age of 52 for approximately eight years, tracking their consumption of seven widely used low- or no-calorie sweeteners and monitoring their cognitive function through repeated assessments of verbal fluency, working memory, word recall, and processing speed (American Academy of Neurology, 2025, September 3).1

The results were striking. People who consumed the largest total amounts of sweeteners experienced a 62% faster decline in overall thinking and memory abilities than those who consumed the least — a difference the researchers estimated was comparable to roughly 1.6 additional years of cognitive aging. Even those in the middle consumption group experienced a 35% faster decline, equivalent to about 1.3 extra years of aging.

The association was especially pronounced in adults under 60, and was stronger in people with diabetes than in those without it. Since people with diabetes are among the most frequent users of sugar substitutes (because they're advised to use them specifically to manage blood sugar) this finding is particularly significant.

The seven sweeteners studied were aspartame, saccharin, acesulfame K, erythritol, xylitol, sorbitol, and tagatose. Six of the seven — all except tagatose — were associated with faster cognitive decline. The researchers were careful to note that this was an observational study and could not prove that sweeteners caused the cognitive changes. Other factors could help explain the pattern. But the consistency and size of the association across nearly 13,000 people over eight years is not something to dismiss lightly.

The mechanisms aren't fully established, but several plausible pathways have been proposed in the research literature.

Aspartame is metabolized into methanol and then formaldehyde in the body, which can generate free radicals and oxidative stress. Some animal studies have found that aspartame at relatively low doses causes abnormalities in brain chemistry and learning deficits, and there is evidence that it may be able to breach the blood-brain barrier under some conditions (Ravn, 2025, October 10).2 Aspartame also produces phenylalanine as a breakdown product, which in large amounts can affect neurotransmitter balance.

A second and increasingly important pathway involves the gut-brain axis. Research has established that the gut microbiome communicates continuously with the brain through neural, immune, and endocrine signaling pathways. Disruption of the gut microbiome (called dysbiosis) can compromise the intestinal barrier, increase systemic inflammation through the release of bacterial endotoxins into the bloodstream, and trigger neuroinflammation that impairs cognitive function (Tana, Moffa, Tana, Ucciferri, and Moffa, 2025; Rundek et al. 2021).3, 4 Several artificial sweeteners, particularly sucralose and saccharin, have demonstrated bacteriostatic effects on gut bacteria, meaning they inhibit bacterial growth and can alter the composition of the microbiome in ways that tip it toward a pro-inflammatory state (Basson, Rodriguez-Palacios, and Cominelli, 2021; Xiaofa, 2014).5, 6​

as we'll discuss below.

What we know about the specific sweeteners:

Aspartame:
Found in diet sodas, many flavored drinks, tabletop sweeteners like Equal and NutraSweet, and thousands of processed food products. It was the sweetener most commonly discussed in the new Brazilian study's high-consumption group, and earlier research has linked it to oxidative stress and neurochemical changes in animals. The amount consumed by the highest intake group in the study was roughly equivalent to the aspartame in one can of diet soda per day.

Saccharin:
One of the oldest artificial sweeteners, found in Sweet'N Low and many processed foods. Epidemiological data from several countries has shown that spikes in IBD incidence have followed regulatory approval of saccharin in their markets — a correlation that has been noted in academic literature as potentially more than coincidental. Saccharin has demonstrated inhibitory effects on intestinal bacteria, and its decline in use in the late 1970s and early 1980s following cancer concerns was followed by a decrease in IBD rates in some regions.

Acesulfame K:
A high-intensity sweetener frequently used in combination with aspartame or sucralose to improve flavor in diet beverages and processed foods. It was among the six sweeteners associated with cognitive decline in the new study.

Sorbitol:
A sugar alcohol found naturally in some fruits and used widely in sugar-free candies, gum, baked goods, and medications. It was consumed in the largest quantity of any individual sweetener among the Brazilian study's participants, averaging 64 mg per day in the overall population. Sorbitol is also a well-established osmotic laxative — it draws water into the colon, which can cause bloating, cramping, and diarrhea even in people with healthy digestive systems (Mäkinen, 2016).7 For MC patients, this effect is relevant and serious.

Xylitol:
Another sugar alcohol, common in sugar-free gum, mints, and dental products. Like sorbitol, it's poorly absorbed in the small intestine, reaches the colon largely intact, and can cause osmotic diarrhea in sensitive individuals. Recent cardiovascular research has also raised concerns about xylitol's effects on platelet reactivity, suggesting potential links to increased clotting risk (Witkowski et al., 2023).8

Erythritol:
Generally considered the best-tolerated sugar alcohol from a gastrointestinal standpoint because most of it is absorbed in the small intestine before reaching the colon, minimizing the osmotic diarrhea effect that makes sorbitol and xylitol problematic. However, it was still among the six sweeteners linked to cognitive decline in the new study, and at high doses it can still cause nausea, bloating, and loose stools.

Tagatose:
The one sweetener in the study that was not associated with cognitive decline, and the exception is notable because tagatose has a meaningfully different biological profile from the others. It has a glycemic index of just 3 (compared to 65 for table sugar), acts as a prebiotic by generating short-chain fatty acids in the gut, and may actually support beneficial gut bacteria rather than disrupting them (Spinner, 2024, September 5; Durante et al., 2021).9, 10 Researchers at Tufts University recently developed a more efficient production method for tagatose, which may make it more widely available and affordable. It is already FDA-designated as generally recognized as safe (Love et al., 2025).11 For MC patients who need a sweetener, tagatose appears to be the most promising option currently available, although large quantities may still cause some GI discomfort in susceptible individuals, and human evidence on long-term effects remains limited.​

For most people, the cognitive findings in this study are the central concern. For MC patients, there's a second layer of risk that has received almost no attention in news coverage of the study. Several of these sweeteners have documented adverse effects on the gut that are especially dangerous for people with inflammatory bowel disease.

Sucralose, one of the most widely used sweeteners in the world, though not among the seven specifically studied in the new Brazilian research, has been shown in multiple animal studies to worsen gut inflammation in models of IBD, including both Crohn's disease and ulcerative colitis. It promotes dysbiosis, increases inflammatory markers, weakens the gut barrier, and stimulates the development of colonies of-invasive E. coli — the same pathogenic bacteria linked to soybean oil's effects on the gut (Rodriguez-Palacios et al., 2018).12 Research has also shown that sucralose worsens gut damage and promotes colitis-associated colorectal cancer risk in animal models (Li et al., 2020).13 About 10% to 15% of IBD patients report that artificial sweeteners worsen their symptoms — a figure that almost certainly understates the true proportion, since many patients don't connect their sweetener use to their symptoms.

Saccharin and acesulfame K have also been linked to IBD promotion through their inhibitory effects on intestinal bacteria. The concern is that these sweeteners remain in the gastrointestinal tract for extended periods, inhibit bacterial growth, reduce the bacterial populations that normally inactivate digestive proteases in the lower gut, and may thereby contribute to the protease-driven intestinal damage that's a feature of IBD pathogenesis.

Sorbitol and xylitol carry direct osmotic risks for MC patients. Both are classified as FODMAPs — fermentable carbohydrates that are poorly absorbed and highly fermentable in the colon. For someone whose gut is already compromised and whose colon responds to osmotic challenges with diarrhea and urgency, even moderate amounts of these sugar alcohols can trigger or worsen symptoms. Sorbitol in particular is a medically recognized laxative; it's not a dietary option that MC patients can safely use without caution.

The gut-brain connection adds another dimension. Research has increasingly established that gut dysbiosis can drive neuroinflammation through the gut-brain axis — that is, a disrupted and inflamed gut can contribute to cognitive impairment through systemic inflammation that reaches the brain. MC patients already have a disrupted gut environment and often experience brain fog that correlates with disease activity. Sweeteners that further disrupt the gut microbiome could theoretically worsen both gut symptoms and the cognitive effects they contribute to — a compounding problem rather than two separate ones.​

The Brazilian study's lead author specifically noted that more research is needed on alternatives such as applesauce, honey, maple syrup, and coconut sugar.1 None of those were studied, and for MC patients some of them carry their own risks depending on individual tolerance. Honey and maple syrup contain fructose and other sugars that can be problematic during flares. Applesauce is tolerated by many MC patients but contains sorbitol naturally — a consideration for those who are particularly sensitive.

Stevia and monk fruit were not included in the Brazilian study and were not among the sweeteners linked to cognitive decline. Neither has been associated with the gut dysbiosis effects documented for sucralose and saccharin, though animal research on stevia and the gut microbiome has produced mixed results that are not yet conclusive in humans. For MC patients who need a sweetener during remission, stevia appears to be one of the lower-risk options based on current evidence, as does tagatose — with the caveat that large amounts of either may not be well tolerated by everyone.

The picture that emerges from this research is that most of the commonly used sugar substitutes carry risks we weren't fully informed about when we started using them. Six of the seven sweeteners examined in a rigorous eight-year study of nearly 13,000 people were associated with measurable cognitive decline. Several of those same sweeteners have independent evidence linking them to gut dysbiosis, worsened IBD symptoms, and intestinal barrier damage. And the population most frequently advised to use sugar substitutes — people with diabetes — is the same population in which the cognitive effects appear to be strongest.

For MC patients, this isn't an abstract concern. Many of us use these sweeteners daily in beverages, medications, and processed foods, often without realizing they're there. They appear on labels under multiple names and are present in products that don't advertise themselves as sugar-free.

The most practical steps we can take are to read labels carefully and identify which sweeteners we're currently consuming, give particular priority to avoiding sorbitol, xylitol, saccharin, sucralose, and acesulfame K, consider shifting to tagatose or stevia as primary sweeteners if we need one, and discuss with our care team whether our current sweetener use is consistent with our gut health goals.
​
As with so many things in MC management, the safest approach is the most whole-foods-based one — meaning that reducing our dependence on sweetened products of any kind, artificial or otherwise, is probably the most protective step we can take for both our gut and our brain.

1. American Academy of Neurology. (2025, September 3). Study links high intake of artificial sweeteners to faster cognitive decline. Retrieved from https://www.news-medical.net/news/20250903/Study-links-high-intake-of-artificial-sweeteners-to-faster-cognitive-decline.aspx

2. Ravn, C. (2025, October 10). Does Aspartame Cause Demential? Memory Loss, Sweeteners & Daily Impact. Retrieved from https://optoceutics.com/does-aspartame-cause-dementia-alzheimers-memory-loss-artificial/?srsltid=AfmBOopUu25hEibVByI5O-F93d6bWxJT3mS80vs5FkdYTYF-sYYJRxdt

3. Tana, C., Moffa S, Tana, M., Ucciferri, C., and Moffa, L. (2025). Gut Microbiota, Mild Cognitive Impairment and Dementia: A Systematic Review. Neurology International, 17(10). 155. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12566805/

4. Rundek, T., Roy, S., Hornig, M., Cheung, Y. K., Gardener, H., DeRosa, J., . . . Sacco, R. L. (2021). Gut permeability and cognitive decline: A pilot investigation in the Northern Manhattan Study. Brain Behavior & Immunity — Health, 12:100214. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8186438/

5. Basson, A. R., Rodriguez-Palacios, A., and Cominelli, F. (2021). Artificial Sweeteners: History and New Concepts on Inflammation. Frontiers in Nutrition, 8:746247. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8497813/

6. Xiaofa, Q. (2014). May artificial sweeteners not sugar be the culprit of dramatic increase of inflammatory bowel disease in China? Chinese Medical Journal, 127(17) Retrieved from https://mednexus.org/doi/pdf/10.3760/cma.j.issn.0366-6999.20140673

​7. Mäkinen, K. K. (2016). Gastrointestinal Disturbances Associated with the Consumption of Sugar Alcohols with Special Consideration of Xylitol: Scientific Review and Instructions for Dentists and Other Health-Care Professionals. International Journal of Dentistry, 2016:5967907. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC5093271/

8. Witkowski, M., Nemet, I., Alamri, H., Wilcox, J., Gupta, N., Nimer, N., . . . Hazen, S. L. (2023). The artificial sweetener erythritol and cardiovascular event risk. Nature Medicine, 29, pp 710–718. Retrieved from https://www.nature.com/articles/s41591-023-02223-9

9. Spinner, J. (2024, September 5). Tagatose sweetens with prebiotic benefits: ASR Group. Snack Food & Wholesale Bakery, Retrieved from https://www.snackandbakery.com/articles/112030-tagatose-sweetens-foods-with-lower-gi-and-prebiotic-benefits-asr-group

10. Durante, M., Sgambellone, S., Lucarini, L., Failli. P., Laurino, A., Collotta, D., . . . Collino, M. (2021). D-Tagatose Feeding Reduces the Risk of Sugar-Induced Exacerbation of Myocardial I/R Injury When Compared to Its Isomer Fructose. Frontiers in Molecular Biosciences, 8:650962. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8076855/

11. Love, A., Toomey, C., Kumar, A., Kashyap, S. N., Santhamoorthy, D. K., Muthuraj, L., . . . Santos, C. N. S. (2025). Reversal of the Leloir pathway to promote galactose and tagatose synthesis from glucose. Cell Reports Physical Science, 6(12). 102993. Retrieved from https://www.cell.com/cell-reports-physical-science/fulltext/S2666-3864(25)00592-2

12. Rodriguez-Palacios, A., Harding, A., Menghini, P., Himmelman, C., Retuerto, M., Nickerson, K. P., . . . Cominelli, F. (2018). The Artificial Sweetener Splenda Promotes Gut Proteobacteria, Dysbiosis, and Myeloperoxidase Reactivity in Crohn's Disease-Like Ileitis. Inflammatory Bowel Diseases, 24(5). pp 1005–1020. Retrieved from https://pubmed.ncbi.nlm.nih.gov/29554272/

13. Li, X., Liu, Y., Wang, Y., Li, X., Liu, X., Guo, M., . . . Jiang, M. (2020). Sucralose Promotes Colitis-Associated Colorectal Cancer Risk in a Murine Model Along With Changes in Microbiota. Frontiers in Oncology, 10:710. Retrieved from https://pubmed.ncbi.nlm.nih.gov/32582527/

When a label says avocado oil but the bottle contains soybean oil, microscopic colitis (MC) patients pay a price that goes well beyond the extra money spent at the checkout.

Many of us with MC have switched to avocado oil products in recent years, drawn by the promise of a clean, gut-friendly fat that avoids the seed oils we've learned to be cautious about. We pay more for chips, mayonnaise, and salad dressings labeled "made with avocado oil." We read the ingredient list, see avocado oil listed as the only oil, and feel confident we're making a safe choice.

A new study from the University of California, Davis suggests that confidence is very likely misplaced, and for MC patients sensitive to soy, the consequences can be more than financial.

Researchers at UC Davis purchased 54 packaged food products that listed avocado oil as the only oil ingredient — chips, mayonnaise, and salad dressings, and subjected them to chemical analysis. The results were stark. 89% of the products showed signs of adulteration with cheaper oils, most commonly soybean oil. One sample appeared to contain essentially no avocado oil at all (Godoy, 2026, July 21).1

The findings broke down by product category in a way that should concern anyone relying on these labels. Among chips labeled as made with avocado oil, 93% were adulterated. Among mayonnaises, 71% failed — and when U.S.-made products were examined separately, that figure climbed to 100%. Every single salad dressing product tested was adulterated (Quinton, 2026, July 15).2

Critically, price offered no protection. Products at the higher end of the price range were no more likely to be authentic than cheaper ones. Consumers paying a premium for what they believed was a cleaner oil were being misled just as thoroughly as anyone else.

For comparison, the same researchers tested 20 packaged food products made with olive oil. Only one showed signs of adulteration. As lead researcher Selina Wang, a professor of food science at UC Davis, put it: "So this is largely an avocado oil product problem."

This latest study is actually the third time in six years that UC Davis researchers have documented serious authenticity problems in the avocado oil market. A 2020 study found that 82% of commercially bottled avocado oils were either rancid or adulterated with other oils. A follow-up found similar problems with private-label products. What the new 2026 research confirms is that the fraud didn't clean itself up as the market grew — it expanded right alongside it, moving from bottled oils into the rapidly growing category of packaged foods that trade on the avocado oil label.

The economics make the incentive obvious. Pure avocado oil costs roughly $4 to $5 per pound. Soybean oil costs $0.50 to $1.50. The label premium that consumers pay for avocado oil products is real. The oil itself often isn't.

Investigators haven't been able to pinpoint exactly where in the supply chain the substitution typically occurs, whether at the level of the oil supplier, the ingredient processor, or the food manufacturer. What's clear is that the problem is systemic and that it doesn't leave a detectable trace on the label.

For the general public, buying adulterated avocado oil is primarily a consumer fraud issue — paying premium prices for an inferior product. For MC patients, it can be something considerably more serious.

Soy sensitivity is one of the most common food intolerances in the MC community. According to data shared by members of the Microscopic Colitis Foundation discussion forum, more than half of us are sensitive to soy proteins and related compounds. This figure is consistent with the broader pattern of MC-associated food sensitivities, which also include gluten and casein, and which appear to arise from the increased intestinal permeability (commonly called "leaky gut"), that accompanies the disease. Once the gut barrier is compromised, food proteins that would ordinarily be processed normally can cross into the intestinal wall and trigger an immune response.

Soybean oil presents a somewhat different issue than soy protein. Highly refined soybean oil theoretically contains very little soy protein and is sometimes considered safe for people with soy allergies. However, research on this point is not fully settled, and MC patients react to soy through immune pathways that may not follow the same rules as classic IgE-mediated soy allergy. Interestingly, there is now direct research evidence that soybean oil itself, independent of its protein content, may promote intestinal inflammation through a separate mechanism.

Soybean oil is composed of up to 60% linoleic acid, an omega-6 fatty acid. A research team at UC Riverside found that mice fed a diet high in soybean oil were significantly more susceptible to developing colitis. The mechanism involves linoleic acid's effect on the intestinal endocannabinoid system — it reduces levels of beneficial endocannabinoids in the gut, weakens the intestinal barrier, decreases beneficial bacteria, and promotes colonizing by-invasive E. coli, a strain of bacteria that has been linked to IBD in humans (Pittalwala, 2023, July 3; Deol, et al., 2023).3, 4

Americans already derive far more of their daily energy from linoleic acid than their bodies need — as much as 10%, against a requirement of just 1 to 2%. For MC patients who are already dealing with a compromised intestinal barrier, adding a hidden source of high-linoleic-acid oil through products that are supposed to be free of soybean-oil, compounds a risk that most of us aren't even aware we're taking.

Avocado oil, by contrast, is composed primarily of oleic acid, a monounsaturated omega-9 fat with a very different biological profile. It doesn't carry the same pro-inflammatory omega-6 overdose that makes soybean oil a concern for gut-sensitive individuals. When we choose avocado oil products, that difference is part of what we're paying for. The adulteration findings suggest we're usually not getting it.

The honest answer is that there's no easy solution. Short of having the oil in every product we buy independently tested, which isn't practical, we can't verify authenticity from a label alone, regardless of how confidently the packaging states "made with 100% avocado oil."

Bottled avocado oil from brands with documented third-party testing and supply chain transparency is more likely to be authentic than unverified packaged food products. If we're cooking at home with avocado oil, sourcing from a reputable bottled brand and preparing our own chips, dressings, and sauces gives us considerably more control than trusting a commercial product.

Among packaged foods, the adulteration problem appears worse in some categories than others. The UC Davis study found that salad dressings were uniformly adulterated and chips were nearly so. If we choose to buy these products at all, rotating brands and staying alert to any symptom changes after introducing a new product is a reasonable precaution.

For those of us who react to soy, the safest position, although frustrating, is to treat most commercially packaged "avocado oil" products with the same caution we'd apply to a product with soy listed on the label, at least until the industry develops and enforces meaningful authenticity standards.

The Avocado Oil Manufacturers Association, founded in 2025, has acknowledged the authenticity problem and expressed intent to address it, pointing to the olive oil industry as a model. It took years of published research, public pressure, and eventually, coordinated industry standards, before olive oil adulteration rates dropped to the relatively low levels seen today. The avocado oil industry appears to be at an early stage of that same process.

In the meantime, the burden falls on consumers, as it usually does, to navigate a marketplace where the label and the contents of the package don't reliably match. For MC patients who are already working hard to identify and eliminate foods that trigger symptoms, discovering that a product we trusted has been silently adulterated with one of our most problematic intolerances is a legitimate health concern, not just a shopping inconvenience.

1. Godoy, M. (2026, July 21). Is that food really made with 100% avocado oil? Likely not. MPR, Retrieved from https://www.npr.org/2026/07/21/nx-s1-5902084/avocado-oil-health-fraud-study

2. Quinton, A. (2026, July 15). That Avocado Oil Chip You’re Eating May Not Be Made With Pure Avocado Oil. University of California, Davis, Retrieved from https://www.ucdavis.edu/food/news/avocado-oil-chip-youre-eating-may-not-be-made-pure-avocado-oil

3. Pittalwala, I. (2023, July 3). Widely consumed vegetable oil leads to an unhealthy gut. University of California at Riverside, Retreived from https://news.ucr.edu/articles/2023/07/03/widely-consumed-vegetable-oil-leads-unhealthy-gut

4. Deol, P., Ruegger. P., Logan, G.D., Shawki, A., Li, J., Mitchell, J. D., . . . Sladek, F. M. (2023). Diet high in linoleic acid dysregulates the intestinal endocannabinoid system and increases susceptibility to colitis in Mice. Gut Microbes, 15(1). 2229945. Retrieved from https://pubmed.ncbi.nlm.nih.gov/37400966/

Because PAR2 continues signaling inside endosomes where traditional drugs cannot reach, researchers developed nanoparticles that deliver PAR2 blockers directly into endosomes.

How the nanoparticles work:
These engineered nanoparticles act as "Trojan horses":​

1. They are swallowed by intestinal cells and sensory neurons
2. Instead of escaping endosomes (like most drug carriers), they deliberately remain inside
3. They release a PAR2-blocking drug (AZ3451) precisely where the receptor is firing
4. Pain signals stop at their source​

Results in animal studies show

• long-lasting, powerful pain relief
• Normalization of pain-related behavior
• Reduction of inflammation
• Minimal systemic absorption (much safer than opioids or NSAIDs)

This represents a first-in-class pain therapy targeting intracellular receptors—a completely new approach to managing gut pain.

If this nanotechnology translates successfully to human trials, MC patients could have access to:

• Targeted pain relief without systemic side effects
• Anti-inflammatory effects at the cellular level
• No risk of addiction (unlike opioids)
• No GI damage (unlike NSAIDs, which can trigger MC flares)
• Long-lasting relief from a single dose

​
This could be transformative for the approximately 40% of MC patients who struggle to achieve stable remission with current medications.

​Researchers are now exploring engineered probiotics that secrete PAR2-deactivating enzymes. If successful, such probiotics could:

• Reduce pain naturally
• Restore intestinal barrier function
• Decrease inflammation
• Provide long-term disease control
• Offer a non-drug therapy for MC​

This aligns perfectly with existing MC treatment approaches that emphasize specific probiotic strains like Bifidobacterium infantis 35624, Lactobacillus plantarum 299v, and Saccharomyces boulardii.

These findings do not demonstrate that gut pain, once initiated, is "locked on" simply because PAR2 activation becomes "stuck on". It's more complicated than that, as you will see below.

​This was not part of the original studies cited above, of course, since the studies were designed to promote the development of an expensive medication (or drug) to be used for resolving gut pain. But as most of us are aware, the elimination of inflammatory foods from the diet can restore not only proper digestion, but microbiome balance. And most importantly, it can stop the pain associated with MC.

The fact that the PAR2 recepters get “stuck on” is irrelevant if the inflammation that is causing the activation of those receptors is suppressed, and this can be done by making the proper diet changes to eliminate the inflammation. After that, the pain cycle will naturally stop.

The sensory nerve endings that are responsible for sensing pain in the gut are called nociceptors, and they're a major target for the drugs discussed by the researchers. Endosomes in nociceptors typically last a few hours, up to maybe 24 hours. The descriptions in some of the articles discussing this research leave the impression that the endosomes last much longer, since the pain signaling they produce is "stuck on".

But that interpretation is misleading, because sustained endosomal signaling is necessary for prolonged pain signals, and the only way that the signaling can last for extended periods (days, or longer) is if the endosomes are continually replaced as they cycle out, and this requires that the bacteria must continue to produce the protease that activates the PAR2 receptors.

If the inflammation cycle that triggers the gut pain can be broken by an anti-inflammatory diet, for example, then the prolonged signaling by the PAR2 receptors will dissipate as the inflammation level declines in response to the diet changes.

​Although the PAR2 pain receptors may get "stuck on", as stated by Dr. Nigel Bunnett's team in their research findings — in the long run, this is irrelevant. If they were actually "stuck on" for the long-term, an elimination diet could not eliminate the pain symptoms of MC. To the contrary, a safe diet apparently results in the reduction of bacterial protease production, and lower PAR2 activation, because a safe diet can eliminate not only all the clinical symptoms of MC, but it will eventually restore normal histology to the cells of the colonic epithelia.

The key distinction is this:
A safe diet does not directly “switch off PAR2 receptors”, — it removes the foods and conditions that cause PAR2 activation — which indirectly leads to PAR2 downregulation and mucosal healing (despite the researchers insinuations that the receptors become "stuck on" for the long-term.

So diet is fully capable of normalizing these pathways for the following reasons:

1. The gut microbiome is primarily determined by diet. This is one of the strongest findings in all of gut science. The foods you eat determine which bacterial species survive. Removing inflammatory foods changes the ecological environment. Microbiome shifts occur within 48–72 hours after dietary change.

2. Bacterial protease production depends on which bacteria are present. Bacterial serine proteases (the molecules that activate PAR2) are produced by specific species, such as:

• Enterobacteriaceae
• Bacteroides fragilis
• Certain Proteobacteria
• Dysbiotic Clostridia

When our diet removes the substrate that supports these organisms (certain proteins, emulsifiers, carbohydrates, and additives, for example), their population drops dramatically, and there will be:

• Fewer dysbiotic bacteria
• Fewer proteases
• Less PAR2 activation

Diet changes the species. Species change the proteases. And proteases change the inflammation.

3. The epithelial cells in the colon's lining are replaced very rapidly, with the entire lining being replaced approximately every 3 to 5 days. That ensures that any cells containing "stuck on" PAR2 will be destroyed, and replaced by new cells every 3 to 5 days. Therefore, as the diet changes reduce the general inflammation level in the colon, the newly replaced cells will be less and less likely to be injected with PAR2, so that the inflammation level will eventually return to normal, and any pain associated with the inflammation will dissipate.

That said, the reason that MC and other IBD's are chronic, is because the healing process is corrupted. The first stage of the healing process is inflammation. With IBD's, the healing process is stuck on the first stage, because the inflammation is constantly being regenerated (with almost every meal). But once the diet is modified to remove the inflammatory foods, healing can become "unstuck" and proceed normally.

1. Lakemeyer, M., Latorre, R., Blazkova, K., Lomax, A. E., Bunnett, N. W., and Bogyo, M. (2025). A Bacteroides fragilis protease activates host PAR2 to induce intestinal pain and inflammation. Cell Host & Microbe, 33(10), pp 1686–1702. e11. Retrieved from https://www.cell.com/cell-host-microbe/abstract/

2. Teng, S. L., Latorre, R., Bhansali, D., and Bunnet, N. W. (2025). Nanomedicines targeting protease-activated receptor 2 in endosomes provide sustained analgesia. PNAS, 122(41). e2412687122 Retrieved from https://www.pnas.org/doi/10.1073/pnas.2412687122

Many of us who have microscopic colitis (MC) have noticed increasing symptoms such as flushing, headaches, itching, rash, hives, or worsening diarrhea after eating aged cheeses, fermented foods, or leftovers. These symptoms are almost surely a result of reactions triggered by high-histamine foods (or foods or medications that cause our body to release histamine).

Understanding why this happens, and why it's rarely a single-cause problem. is necessary for effective management.

Histamine balance in our body depends on three factors:

• how much histamine our mast cells release
• how much histamine we consume in food (and medications and supplements)\
• how efficiently our body breaks down and clears histamine

When any of these factors shifts unfavorably, histamine can accumulate and cause symptoms.
For most people, the body handles dietary histamine efficiently through an enzyme called diamine oxidase (DAO), which is produced primarily in the intestinal lining and breaks down histamine in the gut before it can enter circulation. However, in MC patients, this system frequently becomes impaired, not because of a single defect, but through multiple overlapping problems involving nutrient deficiencies, gut damage, and ongoing losses due to chronic diarrhea.

Magnesium stabilizes mast cells, preventing them from releasing histamine inappropriately. It also supports enzyme systems broadly and helps regulate nervous system excitability. When magnesium is deficient (which is extremely common in MC due to chronic diarrhea), mast cells become hyperreactive, releasing more histamine in response to normal triggers.

This acts upstream t the release side of the equation. More histamine is being dumped into our system, even before considering dietary sources or breakdown capacity.

Vitamin B6 is required for proper DAO function. The enzyme simply cannot work efficiently without adequate B6. Deficiency directly reduces DAO activity, meaning histamine from food and from mast cell release accumulates because it's not being broken down at a normal rate. This has a direct effect on our body's primary histamine-clearing mechanism.

Copper supports the structural foundation of DAO. DAO is a copper-dependent enzyme. Copper is built into its molecular structure. Without sufficient copper, our body cannot produce functional DAO enzyme, regardless of how healthy our intestinal lining might be. This is one of the most under-recognized causes of low DAO activity.

Copper deficiency in MC can develop from chronic diarrhea washing out minerals, and from restricted diets that eliminate copper-rich foods. The effect is straightforward — reduced DAO production and dramatically reduced DAO activity.

Vitamin C helps degrade histamine and reduces mast cell activation. When levels are low, circulating histamine increases and clearance slows. While vitamin C isn't as direct a factor as B6 or copper for DAO function, it plays an important supporting role in overall histamine metabolism.

Zinc maintains the intestinal lining and regulates immune response. Deficiency increases gut permeability (leaky gut), allowing more food antigens to reach immune cells, which triggers more histamine release. Deficiency also disrupts immune balance, potentially increasing mast cell activation. This creates a vicious cycle — zinc deficiency worsens gut integrity, which increases antigen exposure, which triggers more immune activation and histamine release.

Vitamin D regulates immune and mast cell activity. Deficiency leads to increased inflammatory signaling and greater mast cell activation, meaning more histamine release even from normal, everyday triggers.

Each of these deficiencies can independently push our system toward histamine intolerance:

• Low magnesium means more histamine released from mast cells
• Low B6 or copper means less histamine broken down by DAO
• Low vitamin C means slower overall histamine clearance
• Low zinc means more gut-driven immune activation triggering release
• Low vitamin D means increased inflammatory tone and mast cell reactivity

​
Any single one of these deficiencies can tip a borderline system into symptomatic histamine intolerance. However, the real problem in MC is synergy. These deficiencies don't just add together — they multiply each other's effects.

Here's how the cascade typically develops in MC:

Step One: MC causes chronic diarrhea and nutrient loss.

Magnesium, zinc, and B6 levels drop from constant losses in watery stool. These minerals and vitamins are water-soluble or poorly retained during rapid transit.

Step Two: Gut inflammation reduces DAO production.

The inflamed, damaged intestinal lining has fewer healthy cells capable of producing DAO enzyme. Even if nutrient levels were perfect, DAO production would be compromised.

Step Three: Copper deficiency develops.

Between diarrheal losses and dietary restrictions (many MC patients limit foods to manage symptoms), copper intake and absorption decline. The DAO enzyme that is being produced becomes structurally impaired.

Step Four: Multiple effects converge.

Now we simultaneously have:

• Increased histamine release due to low magnesium and vitamin D
• Increased immune activation from low zinc creating more gut permeability
• Decreased DAO production from intestinal inflammation
• Decreased DAO function from low B6 and copper
• Reduced histamine clearance from low vitamin C

​The result is histamine overload from both directions — more histamine is being released by hyperactive mast cells, and less histamine is being broken down by impaired DAO.

Many MC patients discover magnesium or vitamin C, supplement it, and feel better briefly. Then symptoms return. Here's why: single-nutrient approaches typically fail:

With supplementary magnesium, which stabilizes mast cells, and reduces histamine release, we feel improvement. However, our DAO is still impaired because B6 and copper remain low. Histamine still accumulates from dietary sources and any remaining mast cell activity. Within weeks, symptoms return despite continued magnesium supplementation.

The problem is that we've addressed one piece of a multi-piece puzzle. The other deficiencies are still undermining histamine metabolism.

Effective management requires addressing multiple layers simultaneously, not sequentially.

Layer One: Stabilize mast cells to reduce histamine release.

• Magnesium supplementation (glycinate form, 300-400 mg daily)\
• Vitamin D optimization (test levels, supplement if deficient)

Layer Two: Restore DAO function:

• Vitamin B6 supplementation (P5P form preferred, 25-50 mg daily)
• Copper assessment and careful supplementation if deficient (copper must be balanced with zinc — 10 to 15 mg of zinc to 1 mg of copper — don't supplement blindly)

Layer Three: Improve histamine clearance:

• Vitamin C supplementation (but moderate doses to avoid GI upset, 500-1000 mg daily, split into doses, or use time-release capsules)

Layer Four: Repair gut environment:
​

• Continue identifying and eliminating food triggers.
• Support intestinal healing with appropriate MC treatment (budesonide if needed).
• Address any remaining inflammation

Layer Five: Monitor and adjust:
​

• Work with a physician to test nutrient levels (RBC magnesium, vitamin D, copper, zinc).
• Adjust supplementation based on actual deficiencies, not assumptions.
• Retest periodically to ensure levels normalize.

If we're experiencing histamine sensitivity symptoms alongside MC, we should consider this approach:

Immediate steps:

• Begin magnesium glycinate supplementation (start low, increase gradually).
• Add vitamin C in moderate doses.
• Request comprehensive nutrient testing from our physician.

Short-term (within 1-2 months):

• Add vitamin B6 (P5P form) if testing shows deficiency or low-normal levels.
• Optimize vitamin D levels.
• Consider DAO enzyme supplements as a temporary measure while addressing underlying deficiencies.
  
  

Long-term:

• Work with a dietitian to ensure your restricted diet still provides adequate nutrients.
• Continue MC treatment to reduce intestinal inflammation and restore DAO production.
• Gradually reintroduce high-histamine foods as tolerance improves with nutrient repletion.

Histamine intolerance in MC is rarely a single deficiency problem — it's a network failure involving gut damage, multiple interacting nutrient deficiencies, and ongoing losses from chronic diarrhea. The deficiencies work synergistically, meaning their combined effect is greater than the sum of their individual effects.

This explains why histamine problems in MC patients often feel overwhelming and why simple solutions like "just take DAO" or "just avoid high-histamine foods" rarely work long-term. You're dealing with a systemic problem that requires systemic solutions.

The good news is that when you address multiple nutritional deficiencies simultaneously, support gut healing, and maintain adequate nutrient levels despite ongoing losses, many MC patients see significant improvement in histamine tolerance. Foods that previously triggered immediate reactions become tolerable again. The constant background symptoms of flushing, itching, headaches, and anxiety improve.

But this requires patience, comprehensive supplementation guided by testing, continued MC treatment to reduce gut inflammation, and working with healthcare providers who understand the complex interaction between MC, nutrient status, and histamine metabolism. It's not a quick fix, but it's an achievable goal based on understanding the actual mechanisms that interact to cause the problem.